According to the latest financial report of Regulus Therapeutics, the latest earnings per share (TTM) for the company is -0.17. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about Regulus Therapeutics's free cash flow? The latest report shows it as -11.72M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Regulus Therapeutics shows that the company's current ratio is 19.06, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Regulus Therapeutics, the quick ratio is 17.95, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of Regulus Therapeutics? The latest ROE figure is -10.73%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Regulus Therapeutics, the total asset return on investment (ROA) is -10.11%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Regulus Therapeutics's latest financial report to see how their gross margin is doing - currently at 100.00%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Regulus Therapeutics, the net profit margin is -26.44%, which is a good sign for its profitability.